Poolbeg Pharma is set to make an impact at BioTrinity 2025, a premier event in the life sciences sector. As the conference continues to expand, bringing together the brightest minds and the most innovative companies, Poolbeg Pharma stands at the forefront, ready to showcase its cutting-edge advancements in biotech.
BioTrinity, now in its 19th year, remains a key catalyst for growth, connecting investors, R&D pioneers, and major industry players. The 2025 event promises an enriched experience with an expanded programme, featuring dual-track presentations from Series A-stage R&D companies spanning 14 therapy areas. Attendees can engage with a high-profile business and investment track, an exhibitor showcase, private partnering meetings, and an academic poster presentation. This convergence of expertise and capital creates an ideal environment for investment and collaboration.
Following a sell-out success in 2024, BioTrinity 2025 is expected to draw around 900 delegates, including investors, pharmaceutical executives, academics, and service providers from across the globe. With participation from the UK, Europe, the U.S., Japan, China, and Australia, the conference fosters a dynamic exchange of ideas, breakthroughs, and funding opportunities.
As Poolbeg Pharma continues its journey of innovation in infectious disease and immunology, BioTrinity 2025 presents a prime opportunity to engage with investors and industry leaders. The company remains committed to transforming drug development through its proprietary platforms and agile business model, ensuring that promising therapies reach the market efficiently and effectively.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
